[go: up one dir, main page]

BR0113046A - Derivados de benzimidazol, preparação dos mesmos e aplicação dos mesmos em terapia - Google Patents

Derivados de benzimidazol, preparação dos mesmos e aplicação dos mesmos em terapia

Info

Publication number
BR0113046A
BR0113046A BR0113046-3A BR0113046A BR0113046A BR 0113046 A BR0113046 A BR 0113046A BR 0113046 A BR0113046 A BR 0113046A BR 0113046 A BR0113046 A BR 0113046A
Authority
BR
Brazil
Prior art keywords
optionally substituted
hydrogen atom
preparation
application
group
Prior art date
Application number
BR0113046-3A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0010419A external-priority patent/FR2812878B1/fr
Priority claimed from FR0014696A external-priority patent/FR2816619B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR0113046A publication Critical patent/BR0113046A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

"DERIVADOS DE BENZIMIDAZOL, PREPARAçãO DOS MESMOS E APLICAçãO DOS MESMOS EM TERAPIA". A invenção refere-se a derivados de benzimidazol de fórmula geral (I) na qual X representa um átomo de nitrogênio ou um átomo de carbono e no caso em que X representa um átomo de nitrogênio: R3 representa um átomo de hidrogênio ou um grupo (C1-C4) alquila ou não existe para fornecer compostos de fórmula (I) que envolvem uma amina secundária ou terciária, R4 representa um átomo de hidrogênio ou um grupo (C1-C6) alquila, (C3-C7) cicloalquila, (C3-C7) heterocicloalquila, eventualmente substituído, (CH~ 2~)~ p~-heteroarila, heteroarilcarbonila, fenilcarbonila, (C1-C6) alquilcarbonila,-(CH~ 2~)~ p~COOR, fenilsulfonila eventualmente substituído ou-(CH~ 2~)~ p~-fenila eventualmente substituído e no caso em que X representa um átomo de carbono: R3 representa um átomo de hidrogênio ou um grupo -NR5R6, -N(R5)~ 3~^ +^, -NHCOR7, -CONHR5, -COR7, -NHCONH~ 2~, -OH ou -CH~ 2~OH, R4 representa um átomo de hidrogênio ou um grupo -(CH~ 2~)~ p~-fenila eventualmente substituído, -(CH~ 2~)~ p~-heteroarila ou -(CH~ 2~)~ t~NR7R8. Aplicação em terapia para a preparação de um medicamento destinado à prevenção ou ao tratamento das desordens nas quais está implicada a enzima poli (ADP-ribose) polimerase.
BR0113046-3A 2000-08-08 2001-08-06 Derivados de benzimidazol, preparação dos mesmos e aplicação dos mesmos em terapia BR0113046A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0010419A FR2812878B1 (fr) 2000-08-08 2000-08-08 Derives de benzimidazole, leur preparation et leur application en therapeutique
FR0014696A FR2816619B1 (fr) 2000-11-15 2000-11-15 Derives de benzimidazole, leur preparation et leur application en therapeutique
PCT/FR2001/002556 WO2002012239A1 (fr) 2000-08-08 2001-08-06 Derives de benzimidazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BR0113046A true BR0113046A (pt) 2003-07-01

Family

ID=26212570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113046-3A BR0113046A (pt) 2000-08-08 2001-08-06 Derivados de benzimidazol, preparação dos mesmos e aplicação dos mesmos em terapia

Country Status (28)

Country Link
US (2) US6794382B2 (pt)
EP (1) EP1309594B1 (pt)
JP (1) JP2004505975A (pt)
KR (1) KR20030020450A (pt)
CN (1) CN1446218A (pt)
AR (1) AR030121A1 (pt)
AT (1) ATE284886T1 (pt)
AU (1) AU2001282267A1 (pt)
BG (1) BG107460A (pt)
BR (1) BR0113046A (pt)
CA (1) CA2412368A1 (pt)
CZ (1) CZ294493B6 (pt)
DE (1) DE60107859T2 (pt)
EA (1) EA005950B1 (pt)
EE (1) EE200300048A (pt)
ES (1) ES2233671T3 (pt)
HK (1) HK1053118A1 (pt)
HR (1) HRP20030081A2 (pt)
HU (1) HUP0301514A2 (pt)
IL (1) IL153708A0 (pt)
IS (1) IS6661A (pt)
MX (1) MXPA03000753A (pt)
NO (1) NO20030596L (pt)
PL (1) PL365080A1 (pt)
PT (1) PT1309594E (pt)
SK (1) SK1582003A3 (pt)
WO (1) WO2002012239A1 (pt)
YU (1) YU7203A (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
WO2004108723A1 (en) * 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
AR051294A1 (es) * 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
TW200626139A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CN101084211A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CA2580860A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006034441A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP2008526815A (ja) * 2005-01-11 2008-07-24 ノイロサーチ アクティーゼルスカブ 低コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしての新規２−アミノベンゾイミダゾール誘導体及びそれらの使用
EP2029138A1 (en) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
BRPI0614168A2 (pt) * 2005-08-05 2017-07-25 Astrazeneca Ab Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
US20090239880A1 (en) * 2006-07-03 2009-09-24 Ulrik Svane Sorensen Combinations of monoamine reuptake inhibitors and potassium channel activators
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN103923088B (zh) * 2013-01-11 2016-09-07 上海汇伦生命科技有限公司 2,5-二氮杂双环[2.2.1]庚烷类化合物和制备方法、其药用组合物及其在医药上的应用
EP3581576B1 (en) 2013-03-15 2022-01-26 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
TWI735002B (zh) 2014-04-23 2021-08-01 美商英塞特公司 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮
US10494380B2 (en) * 2015-05-29 2019-12-03 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
TWI786050B (zh) 2016-06-20 2022-12-11 美商英塞特公司 Ｂｅｔ抑制劑之結晶固體形式
CN110661676B (zh) * 2018-06-29 2022-06-28 大唐移动通信设备有限公司 一种带宽部分的测量方法、配置方法、终端及网络设备
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710915B1 (fr) 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
FR2731708B1 (fr) * 1995-03-13 1997-04-30 Synthelabo Derives de piperidine, leur procede de preparation et leur application en therapeutique
EP1133477B1 (de) * 1998-11-27 2004-02-18 Abbott GmbH & Co. KG Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Also Published As

Publication number Publication date
MXPA03000753A (es) 2003-10-15
HRP20030081A2 (en) 2005-02-28
KR20030020450A (ko) 2003-03-08
NO20030596L (no) 2003-04-01
YU7203A (sh) 2006-01-16
SK1582003A3 (en) 2003-08-05
HK1053118A1 (en) 2003-10-10
US20030203893A1 (en) 2003-10-30
US20050032779A1 (en) 2005-02-10
ES2233671T3 (es) 2005-06-16
PL365080A1 (en) 2004-12-27
DE60107859D1 (de) 2005-01-20
AU2001282267A1 (en) 2002-02-18
EP1309594A1 (fr) 2003-05-14
ATE284886T1 (de) 2005-01-15
JP2004505975A (ja) 2004-02-26
EA005950B1 (ru) 2005-08-25
CN1446218A (zh) 2003-10-01
EE200300048A (et) 2004-12-15
WO2002012239A1 (fr) 2002-02-14
DE60107859T2 (de) 2005-12-22
CZ294493B6 (cs) 2005-01-12
CZ2003354A3 (cs) 2003-05-14
BG107460A (bg) 2003-09-30
US6794382B2 (en) 2004-09-21
IL153708A0 (en) 2003-07-06
HUP0301514A2 (hu) 2003-09-29
PT1309594E (pt) 2005-04-29
IS6661A (is) 2002-12-19
EP1309594B1 (fr) 2004-12-15
AR030121A1 (es) 2003-08-13
NO20030596D0 (no) 2003-02-06
EA200201259A1 (ru) 2003-06-26
CA2412368A1 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
BR0113046A (pt) Derivados de benzimidazol, preparação dos mesmos e aplicação dos mesmos em terapia
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AP1687A (en) Therapeutic biaryl derivatives.
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
BR0112475A (pt) N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina
BR0109703A (pt) Derivados de piperazina
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
MXPA03011998A (es) Pirrolopirimidinas como inhibidores de protein cinasa.
BR0010938A (pt) Derivados da 13-metil eritromicina
MY129796A (en) Novel anti-inflammatory androstane derivatives
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
MXPA05006196A (es) Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
UA88773C2 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
BR0209930A (pt) Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto
BR0116365A (pt) Uso de um composto, composto, derivado de 3-indolina, composição farmacêutica, e, método de tratamento de sintomas positivos ou negativos
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
DK0579833T3 (da) Ethanolaminderivater med anti-pollakisuria-virkning

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6AE7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.